SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Parentheticals (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash and Cash Equivalents {1}
Company maintains cash and cash equivalents balances	$ 250,000
Deferred Financing Costs
Amortization of deferred financing costs related to convertible debt		$ 4,835
Research and Development
Clinical Studies expenses - fees, charges and related expenses	1,033,000	1,971,000
Stock Based Compensation
Compensation expenses recorded	464,577	106,379
Common shares from convertible debentures and related accrued interest	73,883,330	47,824,956
Common shares from outstanding warrants	14,705,818	9,053,005
Advertising Costs
Advertising costs are charged to operations when incurred	0	$ 0
Concentrations of Credit Risk
Company maintains cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation ("FDIC") limit.	$ 250,000